Literature DB >> 34159616

TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells.

Jana Koch1,2,3, Zina M Uckeley1,2,3, Patricio Doldan1,3, Megan Stanifer1,4, Steeve Boulant1,3,5, Pierre-Yves Lozach1,2,3,6.   

Abstract

SARS-CoV-2 is a newly emerged coronavirus that caused the global COVID-19 outbreak in early 2020. COVID-19 is primarily associated with lung injury, but many other clinical symptoms such as loss of smell and taste demonstrated broad tissue tropism of the virus. Early SARS-CoV-2-host cell interactions and entry mechanisms remain poorly understood. Investigating SARS-CoV-2 infection in tissue culture, we found that the protease TMPRSS2 determines the entry pathway used by the virus. In the presence of TMPRSS2, the proteolytic process of SARS-CoV-2 was completed at the plasma membrane, and the virus rapidly entered the cells within 10 min in a pH-independent manner. When target cells lacked TMPRSS2 expression, the virus was endocytosed and sorted into endolysosomes, from which SARS-CoV-2 entered the cytosol via acid-activated cathepsin L protease 40-60 min post-infection. Overexpression of TMPRSS2 in non-TMPRSS2 expressing cells abolished the dependence of infection on the cathepsin L pathway and restored sensitivity to the TMPRSS2 inhibitors. Together, our results indicate that SARS-CoV-2 infects cells through distinct, mutually exclusive entry routes and highlight the importance of TMPRSS2 for SARS-CoV-2 sorting into either pathway.
© 2021 The Authors. Published under the terms of the CC BY NC ND 4.0 license.

Entities:  

Keywords:  COVID-19; Coronavirus; SARS-CoV-2; protease; virus entry

Year:  2021        PMID: 34159616     DOI: 10.15252/embj.2021107821

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  49 in total

1.  Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.

Authors:  Angela Serra; Michele Fratello; Antonio Federico; Ravi Ojha; Riccardo Provenzani; Ervin Tasnadi; Luca Cattelani; Giusy Del Giudice; Pia A S Kinaret; Laura A Saarimäki; Alisa Pavel; Suvi Kuivanen; Vincenzo Cerullo; Olli Vapalahti; Peter Horvath; Antonio Di Lieto; Jari Yli-Kauhaluoma; Giuseppe Balistreri; Dario Greco
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

2.  Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs.

Authors:  Boris Bonaventure; Ana Luiza Chaves Valadão; Antoine Rebendenne; Priyanka Roy; Lowiese Desmarets; Mary Arnaud-Arnould; Yves Rouillé; Marine Tauziet; Donatella Giovannini; Jawida Touhami; Yenarae Lee; Peter DeWeirdt; Mudra Hegde; Serge Urbach; Khadija El Koulali; Francisco Garcia de Gracia; Joe McKellar; Jean Dubuisson; Mélanie Wencker; Sandrine Belouzard; Olivier Moncorgé; John G Doench; Caroline Goujon
Journal:  Nat Genet       Date:  2022-07-25       Impact factor: 41.307

3.  Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.

Authors:  David H Drewry; Frances M Potjewyd; Armin Bayati; Jeffery L Smith; Rebekah J Dickmander; Stefanie Howell; Sharon Taft-Benz; Sophia M Min; Mohammad Anwar Hossain; Mark Heise; Peter S McPherson; Nathaniel J Moorman; Alison D Axtman
Journal:  J Med Chem       Date:  2022-09-16       Impact factor: 8.039

4.  Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2.

Authors:  Elena Criscuolo; Benedetta Giuliani; Davide Ferrari; Roberto Ferrarese; Roberta A Diotti; Massimo Clementi; Nicasio Mancini; Nicola Clementi
Journal:  Viruses       Date:  2022-06-07       Impact factor: 5.818

5.  Tunneling nanotubes provide a route for SARS-CoV-2 spreading.

Authors:  Anna Pepe; Stefano Pietropaoli; Matthijn Vos; Giovanna Barba-Spaeth; Chiara Zurzolo
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

Review 6.  The Endolysosomal System: The Acid Test for SARS-CoV-2.

Authors:  Daniella Cesar-Silva; Filipe S Pereira-Dutra; Ana Lucia Moraes Giannini; Cecília Jacques G de Almeida
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

7.  Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.

Authors:  Thanigaimalai Pillaiyar; Philipp Flury; Nadine Krüger; Haixia Su; Laura Schäkel; Elany Barbosa Da Silva; Olga Eppler; Thales Kronenberger; Tianqing Nie; Stephanie Luedtke; Cheila Rocha; Katharina Sylvester; Marvin R I Petry; James H McKerrow; Antti Poso; Stefan Pöhlmann; Michael Gütschow; Anthony J O'Donoghue; Yechun Xu; Christa E Müller; Stefan A Laufer
Journal:  J Med Chem       Date:  2022-06-16       Impact factor: 8.039

Review 8.  Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.

Authors:  Hong Zhou; Wei-Jian Ni; Wei Huang; Zhen Wang; Ming Cai; Yan-Cai Sun
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

9.  Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.

Authors:  Jaspreet Jain; Delia Susan-Resiga; Ursula Andréo; Rachid Essalmani; Alexandra Evagelidis; Rabeb Mouna Derbali; David N Huynh; Frédéric Dallaire; Mélanie Laporte; Adrien Delpal; Priscila Sutto-Ortiz; Bruno Coutard; Claudine Mapa; Keith Wilcoxen; Etienne Decroly; Tram Nq Pham; Éric A Cohen; Nabil G Seidah
Journal:  J Virol       Date:  2022-03-28       Impact factor: 6.549

10.  Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.

Authors:  Huiping Shuai; Jasper Fuk-Woo Chan; Bingjie Hu; Yue Chai; Terrence Tsz-Tai Yuen; Feifei Yin; Xiner Huang; Chaemin Yoon; Jing-Chu Hu; Huan Liu; Jialu Shi; Yuanchen Liu; Tianrenzheng Zhu; Jinjin Zhang; Yuxin Hou; Yixin Wang; Lu Lu; Jian-Piao Cai; Anna Jinxia Zhang; Jie Zhou; Shuofeng Yuan; Melinda A Brindley; Bao-Zhong Zhang; Jian-Dong Huang; Kelvin Kai-Wang To; Kwok-Yung Yuen; Hin Chu
Journal:  Nature       Date:  2022-01-21       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.